Log in to add personal notes on this page.
Genetic heterogeneity describes the situation in which different genetic causes can produce the same (or very similar) phenotype. It is the conceptual opposite of pleiotropy. Two main forms are clinically relevant:
- Locus heterogeneity: variants in different genes cause the same phenotype.
- Allelic heterogeneity: different variants in the same gene cause the same phenotype (or a spectrum of related phenotypes).
A related concept, compound heterozygosity, addresses what happens when an individual carries two different pathogenic variants at the same locus.
Different genes → same phenotype.
| Phenotype | Genes involved (selected) | Implication |
|---|---|---|
| Retinitis pigmentosa | RHO, RPE65, USH2A, RPGR, RP1, and 100+ others | Panel testing required; recurrence risk depends on which gene (AD vs AR vs XL) |
| Charcot-Marie-Tooth (CMT) | PMP22, MPZ, GJB1, MFN2, and 80+ others | Type 1 (demyelinating) vs Type 2 (axonal); inheritance pattern varies by gene |
| Hereditary nonsyndromic deafness | GJB2, GJB6, MYO7A, SLC26A4, and 100+ others | GJB2 alone accounts for >50% of AR cases in some populations |
| Long QT syndrome (LQTS) | KCNQ1 (LQT1), KCNH2 (LQT2), SCN5A (LQT3), and others | Type matters for trigger profile (LQT1 = exercise/swimming; LQT2 = startle/auditory; LQT3 = sleep) and management |
| Hereditary breast/ovarian cancer | BRCA1, BRCA2, PALB2, ATM, CHEK2, RAD51C, RAD51D, and others | Penetrance and tumor spectrum differ by gene; surveillance and risk-reducing surgery decisions are gene-specific |
| Hypertrophic cardiomyopathy | MYH7, MYBPC3, TNNT2, TNNI3, and others | Sarcomeric vs non-sarcomeric; phenocopies (Fabry, amyloidosis) confound the picture |
| Bardet-Biedl syndrome | BBS1–BBS21 (and counting) | Triallelic inheritance described in some families |
Implications of locus heterogeneity
- Panel testing > single-gene testing for phenotypically heterogeneous conditions. Sequencing one gene at a time leaves most patients undiagnosed.
- Inheritance pattern depends on the gene. A "deafness family" with AR transmission via GJB2 has different recurrence risk than one with X-linked POU3F4. Always finish the molecular workup before counseling.
- Genotype-phenotype correlations are gene-specific. LQT1 vs LQT2 have different trigger profiles and treatments; CMT1A vs CMT2A have different electrophysiology and prognosis.
- Phenocopies blur the picture. Some "genetic" phenotypes are actually acquired (Fabry can mimic HCM; B12 deficiency can mimic SCA). Heterogeneity reasoning includes considering non-genetic phenocopies.
Different variants in the same gene → same phenotype, or a phenotypic spectrum.
| Gene | Variant range and effect |
|---|---|
| CFTR | >2,000 reported variants; range from classic CF (F508del) to CBAVD-only or pancreatic-sufficient phenotypes (some milder variants); functional class (I–VI) predicts response to modulator therapy |
| DMD | Reading-frame rule: out-of-frame deletions → DMD (severe, no functional dystrophin); in-frame deletions → BMD (milder, partial dystrophin). Same gene, dramatically different phenotype |
| FMR1 | Repeat-length spectrum: normal (<45), intermediate (45–54), premutation (55–200, gives FXTAS / FXPOI), full mutation (>200, gives Fragile X syndrome). Same locus, different mechanisms by repeat length |
| HBB | Sickle cell disease (HbS), HbC disease, HbE, β-thalassemia (>200 variants); compound heterozygotes (HbS/β-thal) have intermediate phenotypes |
| BRCA1 | Thousands of pathogenic variants; some founder variants (Ashkenazi 185delAG, 5382insC; Icelandic 999del5) recur at high frequency |
| RET | Loss-of-function variants → Hirschsprung disease; specific gain-of-function variants → MEN2A, MEN2B, FMTC. Same gene, opposite mechanism, different syndromes |
Implications of allelic heterogeneity
- Variant interpretation matters as much as gene identification. "Has a CFTR variant" tells you little; "has F508del/F508del" tells you a lot.
- Founder variants matter for risk-stratified screening. Ashkenazi BRCA1/2 panel is three variants because >90% of AJ HBOC traces to them.
- Genotype-phenotype correlation can be precise (DMD reading-frame rule, FMR1 repeat tiers) or messy (CFTR mild variants, BRCA missense). Know which gene gives you which kind of correlation.
- Functional studies sometimes drive interpretation when a missense variant's pathogenicity is unclear.
An individual with two different pathogenic variants at the same locus, one inherited from each parent.
- Common in autosomal recessive disease. Most CF patients carrying F508del are F508del / other-variant compound heterozygotes, not F508del homozygotes (homozygosity is more common in populations with higher inbreeding or strong founder effects).
- Clinical relevance: phenotype reflects the combination, not either variant alone. A "mild" variant paired with a severe one often gives an intermediate phenotype (HbS/β-thal as a classic example, or CFTR severe/mild combinations giving pancreatic-sufficient CF).
- Recurrence calculation: standard AR risks apply (1/4 for each pregnancy from carrier × carrier parents). Both parents must carry one of the variants; testing should confirm which parent contributed which.
- Locus heterogeneity = panel testing. Single-gene Sanger is the wrong approach for heterogeneous phenotypes (deafness, RP, CMT, cardiomyopathies, HBOC). Use a panel or exome.
- Allelic heterogeneity = variant interpretation matters. Don't stop at "has a CFTR variant"; you need the specific variant or pair to counsel.
- Compound heterozygosity is the rule, not the exception, in AR. Don't assume homozygosity unless the family is consanguineous or the population has a strong founder effect.
- Heterogeneity and pleiotropy can coexist. A patient may have a syndrome that's both pleiotropic (one gene → many features) AND locus-heterogeneous (many genes → that syndrome). Marfan is pleiotropic (FBN1 → many features), but Marfan-overlap phenotypes are locus-heterogeneous (TGFBR1/2, SMAD3 → similar overlapping presentations).
- The mutational mechanism may differ across loci within a heterogeneous phenotype. RP genes can be AR loss-of-function, AD gain-of-function, or X-linked; the inheritance pattern is gene-specific even within a single phenotype.
Genetic heterogeneity: many genetic causes → one phenotype (testing strategy = panel). Pleiotropy: one gene → many phenotypes (counseling strategy = surveillance for full spectrum).